Aarti Industries Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹19.1K Cr
The company expects many long-term contract discussions to conclude in the coming financial year, contributing to more robust and secure supply chains. The company targets an EBITDA run rate of INR1,800 crore driven by cost initiatives and new assets like MPP, Zone IV, and UPL JV, with no change in potential though some delay in realization by 6-7 months.
From Aarti Industries's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹527.2
Market Cap
₹19.1K Cr
P/E Ratio
36.6
How does Aarti Industries rank in Chemicals & Petrochemicals?
Compare Aarti Industries against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Aarti Industries — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.2K Cr, net profit ₹137 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company expects many long-term contract discussions to conclude in the coming financial year, contributing to more robust and secure supply chains.
- →Incremental partnerships and joint ventures are intended to meaningfully contribute to business growth and improve earnings quality over the next couple of years.
- →Zone IV asset utilization is expected to improve in the coming financial year, enhancing capacity and production volumes.
- →Despite near-term challenges like the West Asia war and raw material price volatility, the firm remains committed to its growth trajectory.
- →Operating leverage and cost optimization initiatives are on track to support profitability and revenue growth.
- →The company anticipates stabilization or correction in raw material pricing, which should support working capital and EBITDA improvement.
- →New long-term contracts and asset commissioning (e.g., MPP and PEDA plants) are expected to drive growth within the next two years.
- →Domestic market growth is expected to partially offset export demand contractions in discretionary product portfolios like dyes and pigments.
📈 Profitability & Margins
- →The company targets an EBITDA run rate of INR1,800 crore driven by cost initiatives and new assets like MPP, Zone IV, and UPL JV, with no change in potential though some delay in realization by 6-7 months.
- →Margin pressure exists in the agrochemical segment; recovery depends on Chinese industry behavior.
- →EBITDA and cash flow are expected to improve in FY27, aiding net debt reduction from current 3.6x net debt/EBITDA to 2.5x in two years.
- →Volume growth, capacity utilization improvements, and operational efficiencies will contribute to steady earnings growth despite margin pressures.
- →Export growth continues, with careful management of working capital and geopolitical risks.
- →Capex planned around INR750-800 crore in FY27, mainly for Zone IV completion and new long-term contracts, supporting medium-term growth.
- →The company remains cautious about volatile raw material prices impacting working capital and margins, but expects stabilization.
🏗️ Capital Expenditure Plans
- →INR 1,800 crore to INR 2,000 crore capex on Zone IV, including calcium chloride and MPP plants (Page 14)
- →INR 200-250 crore capex for backward integration with a leading global chemical company for a 15-year contract (Page 3)
- →Expansion to 360 KTPA in energy application expected to be commissioned soon (Page 3)
- →No incremental capex required for $150 million multiyear supply agreement with global agrochemical innovator through 2030 (Page 3)
- →Slight delay of 3-4 months in Zone IV project execution due to labor shortages and LPG/election-related migration impacts (Page 12)
- →Capex intensity expected to reduce going forward; cash flow improvement targeted to reduce net debt (Page 16)
💰 Fundraising & Capital Structure
- →No explicit mention of any immediate new fundraising through debt or equity in the provided text.
- →The company is currently managing existing debt, with net debt around INR4,300 crore and efforts to reduce it.
- →Cash flow from operations and capex intensity declining are expected to help reduce net debt in the coming year.
- →A recent term loan was disbursed in late March but was used quickly to reduce debt.
- →Working capital requirements have increased due to raw material prices and export growth, impacting debt marginally.
- →No indication of plans for raising fresh equity; focus remains on internal cash generation and prudent balance sheet management.
📋 Order Book & Pipeline
- →The company has strong order book visibility for FY27, driven by their ability to deliver volume growth and gain market share in the past 18 months.
- →Growth confidence stems from operating assets at higher utilization and maintaining cost competitiveness.
- →Upcoming projects such as the JV with Superform and plastic recyclability initiatives are expected to contribute meaningfully to business.
- →Despite near-term headwinds like the West Asia conflict, the company remains confident about mid-to-long-term growth due to strong positioning and robust order pipeline.
- →Management highlighted ongoing long-term contract renewals and new partnerships that improve earnings visibility.
- →No exact quantitative order book value was disclosed, but qualitative commentary indicates a well-covered and strong pipeline supporting sustainable growth ahead.
Key Metrics
Continue your research
What Aarti Industries Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- NOCIL (Q4 FY26)
The Rs.130 crores capex includes some intermediates and is largely for captive consumption, with part allocated to finished goods. Key concall takeaways from…
- Indo Borax & Chemicals Ltd (Q4 FY26)
175 crores revenue in the previous financial year and Rs. Key concall takeaways from Indo Borax & Chemicals Ltd's Q4 FY26 earnings call — and how it ranks…
- Rossari Biotech (Q4 FY26)
50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments. Key concall takeaways from Rossari…
- Pidilite Inds. (Q4 FY26)
Underlying volume growth (UVG) averaged over 9% per quarter last year, with a ~200 bps increase in FY '25; the company plans to continue lifting UVG…
Frequently Asked Questions
What were Aarti Industries Q4 FY26 results?
The company expects many long-term contract discussions to conclude in the coming financial year, contributing to more robust and secure supply chains. The company targets an EBITDA run rate of INR1,800 crore driven by cost initiatives and new assets like MPP, Zone IV, and UPL JV, with no change in potential though some delay in realization by 6-7 months.
What is Aarti Industries share price analysis?
Aarti Industries currently shows a neutral. The stock trades at a P/E of 36.6 with a market cap of ₹19,123 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Industries planning capital expenditure?
INR 1,800 crore to INR 2,000 crore capex on Zone IV, including calcium chloride and MPP plants (Page 14) - INR 200-250 crore capex for backward integration with a leading global chemical company for a
Keep Aarti Industries on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.